LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission
18 oct. 2022 07h30 HE
|
LEXEO Therapeutics
– LX1004 is an adeno-associated virus (AAV) based gene therapy for the treatment of CLN2 Batten disease – – In a completed Phase 1/2 clinical trial, LX1004 demonstrated a favorable safety profile and...
LEXEO Therapeutics to Present New Clinical Data from its Investigational Gene Therapy LX1001 for APOE4-Associated Alzheimer’s Disease at the 29th European Society of Gene & Cell Therapy Annual Meeting
05 oct. 2022 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, Inc. (LEXEO), a clinical-stage biotech company advancing a pipeline of adeno-associated virus (AAV)-based gene therapy candidates for...
LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
03 mai 2022 07h30 HE
|
LEXEO Therapeutics
Preclinical studies support clinical development of pipeline programs, including novel gene therapies for the treatment of genetically defined cardiovascular and central nervous system diseases NEW...
LEXEO Therapeutics to Participate in Upcoming Investor Conferences
21 mars 2022 07h30 HE
|
LEXEO Therapeutics
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a deep and diverse pipeline of adeno-associated virus (AAV)-based gene...
LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease
02 mars 2022 07h30 HE
|
LEXEO Therapeutics
– In the initial clinical data from low-dose cohort of the ongoing trial, we observed that LX1001 expressed the protective APOE2 protein in the CNS and decreased core Alzheimer’s disease-related...
LEXEO Therapeutics Announces FDA Clearance of Investigational New Drug Application for LX2006, an AAV-based Gene Therapy Candidate for Friedreich’s Ataxia Cardiomyopathy
16 févr. 2022 07h30 HE
|
LEXEO Therapeutics
- Phase 1/2 clinical trial expected to initiate in mid-2022 - - LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate...
LEXEO Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE
|
LEXEO Therapeutics
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases
13 oct. 2021 07h30 HE
|
LEXEO Therapeutics
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing adeno-associated virus (AAV)-mediated treatments for genetic...
LEXEO Therapeutics Closes $100 Million Series B Financing to Advance Clinical Stage Gene Therapy Pipeline and Enhance Preclinical Footprint
09 sept. 2021 06h00 HE
|
LEXEO Therapeutics
Financing led by D1 Capital Partners and Eventide Asset Management with participation from additional investors including returning Series A investors Proceeds to support continued preclinical...
LEXEO Therapeutics Receives Rare Pediatric Disease Designation and Orphan Drug Designation for LX1004 for the Treatment of CLN2 Batten Disease
28 juil. 2021 08h30 HE
|
LEXEO Therapeutics
NEW YORK, July 28, 2021 (GLOBE NEWSWIRE) -- LEXEO Therapeutics, a fully integrated clinical-stage gene therapy company advancing disease-modifying treatments for genetic conditions, today announced...